By concluding a temporary conditional reimbursement with SÚKL the manufacturer
commits to set up a registry to collect information on the clinical effectiveness of the new
drug, treatment costs, and use. Registries are managed in collaboration with the specialised health centres where drugs are made available to patients. Centres need to have a specific
contract with payers and are required to collect information on patient treatment and
outcomes. This information will enable to manufacturer to submit evidence on budget
impact and cost-effectiveness when an agreement comes to an end, which will provide the
basis for SÚKL final reimbursement decision.